0001615774-18-006006.txt : 20180629
0001615774-18-006006.hdr.sgml : 20180629
20180629163040
ACCESSION NUMBER: 0001615774-18-006006
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180628
FILED AS OF DATE: 20180629
DATE AS OF CHANGE: 20180629
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LEDERMAN SETH
CENTRAL INDEX KEY: 0001563420
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36019
FILM NUMBER: 18929636
MAIL ADDRESS:
STREET 1: C/O TONIX PHARMACEUTICALS HOLDING CORP
STREET 2: 509 MADISON AVE., SUITE 306
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Tonix Pharmaceuticals Holding Corp.
CENTRAL INDEX KEY: 0001430306
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 261434750
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 509 MADISON AVE. - SUITE 306
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: 1-800-849-7894
MAIL ADDRESS:
STREET 1: 509 MADISON AVE. - SUITE 306
CITY: NEW YORK
STATE: NY
ZIP: 10022
FORMER COMPANY:
FORMER CONFORMED NAME: TAMANDARE EXPLORATIONS INC.
DATE OF NAME CHANGE: 20080320
4
1
s111120_form4.xml
4
X0306
4
2018-06-28
0
0001430306
Tonix Pharmaceuticals Holding Corp.
TNXP
0001563420
LEDERMAN SETH
C/O TONIX PHARMACEUTICALS HOLDING CORP.
509 MADISON AVENUE, SUITE 306
NEW YORK
NY
10022
1
1
0
0
Chief Executive Officer
Common Stock, $0.001 par value
2018-06-28
4
P
0
500
4.58
A
17166
D
Common Stock, $0.001 par value
22700
I
By 401(k) plan
Common Stock, $0.001 par value
45900
I
By IRA account
Common Stock, $0.001 par value
3100
I
By spouse
Common Stock, $0.001 par value
2917
I
By Leder Laboratories, Inc.
Common Stock, $0.001 par value
2917
I
By Starling Pharmaceuticals, Inc.
Common Stock, $0.001 par value
20463
I
By Lederman & Co., LLC
Common Stock, $0.001 par value
3246
I
By L&L Technologies, LLC
Common Stock, $0.001 par value
5898
I
By Targent Pharmaceuticals, LLC
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.57 to $4.59 per share, inclusive. The reporting person undertakes to provide to Tonix Pharmaceuticals Holding Corp. ("Tonix"), any security holder of Tonix, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
Reporting person may be deemed to be a control person of this entity.
/s/ Seth Lederman
2018-06-29